Company: CERO
Filing Date: 2025-12-05
Form Type: S-1
Source: 0001213900-25-118817
Chunk: 134

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-12-05
Form: S-1
Chunk 134
---
 a merger, tender offer, or proxy contest. These provisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of your choosing or cause us to take other corporate actions you desire. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our Common Stock to decline. If we engage in future acquisitions or strategic partnerships, this may increase capital requirements, dilute stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks. We intend to evaluate various acquisition opportunities and strategic partnerships, including licensing or acquiring complementary drugs, intellectual property rights, technologies or businesses. Any potential acquisition or strategic partnership may entail numerous risks, including:

| ● | increased operating expenses 
 and cash requirements;       |

| ● | the assumption of additional            
 indebtedness or contingent liabilities; |

72

| ● | the issuance of our equity 
 securities;                |

| ● | assimilation of operations,                                                                                               
 intellectual property and drugs of an acquired company, including difficulties associated with integrating new personnel; |

| ● | the diversion of our management’s                                                                                          
 attention from our existing drug programs and initiatives in pursuing such a strategic partnership, merger or acquisition; |

| ● | retention of key employees,                                                                        
 the loss of key personnel and uncertainties in our ability to maintain key business relationships; |

| ● | risks and uncertainties associated                                                                                                      
 with the other party to such a transaction, including the prospects of that party and their existing products or product candidates and 
 marketing approvals; and                                                                                                                |

| ● | our inability to generate revenue                                                                                                          
 from acquired technology and/or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated 
 acquisition and maintenance costs.                                                                                                         |

In addition, if we undertake acquisitions, we may issue dilutive securities, assume or incur debt obligations, incur large one-time expenses and acquire intangible assets that could result in significant future amortization expense. Moreover, we may not be able to locate suitable acquisition opportunities, and this inability could impair our ability to grow or obtain access to technology or products that may be important to the development of our business. Our Bylaws provide that the Court of Chancery of the State of Delaware and, to the extent enforceable, the federal district courts of the United States of America will be the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or